A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Nab-paclitaxel and Gemcitabine versus Nab-paclitaxel and Gemcitabine in Front-Line Metastatic Pancreatic Cancer.

The purpose of this research study is to find out more about the investigational drug, MM-141 and how it interacts with nab-paclitaxel and gemcitabine in patients with newly diagnosed metastatic pancreatic cancer.  The combination of nab-paclitaxel and gemcitabine has improved survival rates for patients with pancreatic cancer; however, many patients do not have long-lasting benefits from the combination.

Contact Candace LeBlanc 508-556-5431 or Marcy Kirkpatrick 508-556-5429 for more information.

For more information about this study: